Further, in acute myeloid leukaemia (AML), HoxB2 and HoxB3 were identified as negative regulators of the FLT3 receptor tyrosine kinase, with their mutations associated with carcinogenic events in around 30% of AML cases [34]. Here, HOXB2 is linked to acute myeloid leukemia.